Home Medicine A decrease in fasting FGF19 levels is associated with the development of non-alcoholic fatty liver disease in obese adolescents
Article
Licensed
Unlicensed Requires Authentication

A decrease in fasting FGF19 levels is associated with the development of non-alcoholic fatty liver disease in obese adolescents

  • Malgorzata Wojcik EMAIL logo , Dominika Janus , Katarzyna Dolezal-Oltarzewska , Anna Kalicka-Kasperczyk , Karolina Poplawska , Dorota Drozdz , Krystyna Sztefko and Jerzy B. Starzyk
Published/Copyright: October 20, 2012

Abstract

Aim: Fibroblast growth factor 19 (FGF19) is a hormone released from the small intestine; recently, it has emerged as an endocrine regulator of glucose and lipid metabolism. The aim of this study was to investigate the role of FGF19 in the development of nonalcoholic fatty liver disease (NAFLD).

Patients: This study included 23 (17 boys) obese adolescents (mean age of 14.1 years) with NAFLD. The control group consisted of 34 (13 boys) obese peers with normal ultrasonographic imaging and normal liver function tests.

Methods: The definition of NAFLD was based on clinical criteria: elevated alanine aminotransferase (>35 U/L) and liver steatosis features on ultrasound imaging. Serum FGF19 levels were measured in a fasting blood sample. The definition of insulin resistance was based on the homeostasis model assessment (HOMA) threshold: >2.5.

Results: There was a significant difference between mean FGF19 levels in patients with NAFLD and controls (142.2 vs. 206 pg/mL, p=0.04). Mean fasting FGF19 levels were decreased in insulin-resistant patients in comparison with the non-insulin-resistant group (155.0 vs. 221.0 pg/mL, p=0.05). There was an inverse correlation between FGF19 and alanine aminotransferase levels (R=–0.3, p<0.05) and triglycerides (R=–0.27, p<0.05).

Conclusion: A decrease in fasting FGF19 is associated with the development of NAFLD in obese adolescents. A decrease in fasting FGF19 levels may be a new important risk factor for NAFLD and the metabolic syndrome in adolescents. Further studies are needed to explain whether exogenous delivery of FGF19 might be therapeutically beneficial.


Corresponding author: Malgorzata Wojcik, MD, PhD, Pediatric and Adolescent Endocrinology Department, Chair of Pediatrics, Jagiellonian University, Collegium Medicum, Ul. Wielicka 265 str., 30-663 Krakow, Poland. Phone: +48-1265812, Fax: +48-6581005

Received: 2012-8-1
Accepted: 2012-9-21
Published Online: 2012-10-20
Published in Print: 2012-12-01

©2012 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. Masthead
  2. Masthead
  3. Review article
  4. The pros and cons of sex steroid priming in growth hormone stimulation testing
  5. Images in pediatric endocrinology
  6. Tuber sinerium hamartoma causing precocious puberty in a child
  7. Original articles
  8. Clinical features suggestive of non-classical 21-hydroxylase deficiency in children presenting with precocious pubarche
  9. Disorders of sex development among Sudanese children: 5-year experience of a pediatric endocrinology clinic
  10. Anti-Müllerian hormone levels in serum 1 year after unilateral orchiopexy
  11. Clinical and genetic analysis of three Chinese patients with steroid 5α-reductase type 2 deficiency
  12. Apparent mineralocorticoid excess syndrome: report of one family with three affected children
  13. A decrease in fasting FGF19 levels is associated with the development of non-alcoholic fatty liver disease in obese adolescents
  14. Acanthosis nigricans predicts the clustering of metabolic syndrome components in Hispanic elementary school-aged children
  15. Nutritional and metabolic findings in patients with Prader-Willi syndrome diagnosed in early infancy
  16. Increased endothelial microparticles in obese and overweight children
  17. The treatment effect of diazoxide on 44 patients with congenital hyperinsulinism
  18. Hyperprolactinemia in children: clinical features and long-term results
  19. Oxidant/antioxidant system markers and trace element levels in children with nutritional rickets
  20. Single-nucleotide polymorphism of the osteoprotegerin gene and its association with bone mineral density in Chinese postmenopausal women
  21. A case of complete androgen insensitivity syndrome with a novel androgen receptor mutation
  22. Patient reports
  23. Mild and severe congenital primary hypothyroidism in two patients by thyrotropin receptor (TSHR) gene mutation
  24. An unusual cause of delayed puberty: Berardinelli-Seip syndrome
  25. Primary hypogonadism in a case with XLAG syndrome
  26. Precocious puberty produced by an osteolipoma of the tuber cinereum
  27. A case of Mayer-Rokitansky-Küster-Hauser syndrome presenting as Graves disease
  28. Priapism in teenage boys following depot testosterone
  29. Spontaneous resolution of pituitary apoplexy in a giant boy under 10 years old
  30. Congenital craniopharyngioma: a case report and literature review
  31. Growth and hormonal profile from birth to adolescence of a girl with aromatase deficiency
  32. Chylomicron retention disease: report of two cases from a Greek Island
  33. Cerebellar metastatic papillary thyroid carcinoma in a pediatric patient with complex congenital heart disease
  34. Hepatic subcapsular steatosis: a rare complication of high dose insulin therapy
  35. Infantile malignant osteopetrosis: a rare cause of neonatal hypocalcemia
  36. Unusual presentations of a girl with Down syndrome: Van Wyk-Grumbach syndrome
  37. Short communications
  38. Cortisol response to the Trier Social Stress Test among Chinese adolescents
  39. Inhaled fluticasone propionate does not influence salivary cortisol when measured with tandem mass spectrometry
Downloaded on 30.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/jpem-2012-0253/html
Scroll to top button